Increased CD133+ cell proliferation, especially with HFBIncreased apoptosisIncreased expression of CD133, CD34, CD38, Osteocalcin, Sparc, Sox‐9, RunX‐2, Stro‐1, CD117/c‐Kit, Oct3/4, Endoglin, and Integrin‐ß1Increased chemosensitivity of CD133(+) cancer cells to various agents. This evidence concerns the gene SPARC and cancer.